steroids and semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment Semaglutide for Weight Loss |

Research on tirzepatide and body composition shows that approximately 75% of weight lost is fat mass and 25% is lean mass

Wegovy (Semaglutide) and Zepbound (Tirzepatide) are FDA-approved, once-weekly injectables designed for adults with obesity or those who are overweight with weight-related health conditions

Reduces pain and bruising: Tissue that has been repeatedly injected becomes more sensitive

Both Hims and Eden offer access to GLP-1 injections and personalized oral weight loss medications

Propensity score matching and covariates Patients in the GLP-1 agonists group were matched to a patient in the non-GLP-1 agonists group using 1:1 propensity score matching (PSM) to reduce confounders 22